The challenge of overcoming resistance to anti-PD(L1)-1 checkpoint inhibitors
24 Sep 2024
Mendocino
Clinical Development
- Why is resistance (e.g., primary and secondary) to PD(L1)-1 inhibitors a significant clinical problem in patients with solid tumors?
- What have been previously tested approaches (e.g., bispecifics, coinhibitory checkpoints, immune agonists) to overcome PD(L1)-1 resistance and why have they been unsuccessful?
- How should we design trials to optimally test novel agents which have demonstrated the potential to overcome PD(L1)-1 resistance?
- What novel compounds or agents directed toward a pathway of interest (e.g., ILT4, IRK, itaconate) are most intriguing?
